Results 161 to 170 of about 197,589 (314)

From Metabolic Crisis to Molecular Classification: Multidisciplinary Management of Synchronous Endometrioid Ovarian and Endometrial Carcinomas With Massive Tumor Burden

Cancer Nexus, EarlyView.
Managing massive tumor burden in synchronous endometrioid carcinomas. The graphical abstract summarizes the clinical pathway from presentation with massive ascites, pleural effusion, and critical metabolic abnormalities to multidisciplinary stabilization, surgical management, integrated morphologic–molecular classification, and shared decision‐making ...
Anna Homeniuk, Leena Abdalla, Sharon Fitzgerald   +2 more
wiley   +1 more source

Spatially interpretable artificial intelligence framework to tailored neoadjuvant dual HER2 blockade in HER2-positive breast cancer. [PDF]

Signal Transduct Target Ther
Wu XR, Lv H, Zhao S, Zeng XH, Dai LJ, Xu YZ, Li YW, Qiu ZY, Huang JT, Zhang NN, Chen L, He M, Zhao YZ, Yang L, Zhou T, Li JJ, Wu J, Jiang YZ, Yang WT, Di GH, Shao ZM, Ma D.   +21 more
europepmc   +1 more source

Association of an Early Resistance Genomic State With Early Progression Following CDK4/6 Inhibitor Therapy in HR+/HER2− Metastatic Breast Cancer

Cancer Nexus, EarlyView.
ABSTRACT CDK4/6 inhibitors combined with endocrine therapy are the standard first‐line treatment for hormone receptor‐positive (HR+) HER2‐negative metastatic breast cancer. However, a substantial proportion of patients experience early disease progression in routine practice. Clinicians currently lack practical tools at treatment initiation to identify
Mobina Shrestha, Salina Dahal, Vishal Mandal, Amir Babu   +3 more
wiley   +1 more source

Receptor discordance between primary tumors and nodal metastases and correlation with the 21-gene recurrence score in early-stage, estrogen receptor-positive, node-positive breast cancer. [PDF]

Breast Cancer Res Treat
Zheng S, Sullivan P, Vadehra K, Kim J, Levee A, Callahan R, Teshome M, Tseng CH, Bardia A, Kapoor NS.   +9 more
europepmc   +1 more source

Systematic Evaluation of Data and Trial Fitness for Oncology Trial Emulation: Empirical Findings from the CARE Initiative

Clinical Pharmacology &Therapeutics, EarlyView.
The Coalition to Advance Real‐World Evidence through Randomized Controlled Trial Emulation (CARE) Initiative seeks to advance understanding of when real‐world data (RWD) can generate valid treatment effectiveness estimates by emulating completed oncology randomized controlled trials (RCTs).
Natalie Levy, Paige Sheridan, Ulka Campbell, David Lenis, Inish O'Doherty, Adina Estrin, Nileesa Gautam, Monica Iyer, Sarah McDonald, Andrew Belli, Gillis Carrigan, K. Arnold Chan, James Chen, Victoria Chia, Neil Dhopeshwarkar, Joy Eckert, Laura Fernandes, Joel Greshock, Rachele Hendricks‐Sturrup, Jenny Huang, XiaoLong Jiao, Sajan Khosla, Orsolya Lunacsek, Lynn McRoy, Yanina Natanzon, Osayi Ovbiosa, Nelson Pace, Simone Pinheiro, Megan Rees, Jennifer Rider, Mothaffar Fahed Rimawi, Travis Robinson, Carla Rodriguez‐Watson, Chithra Sangli, Khaled Sarsour, Sebastian Schneeweiss, Mark Shapiro, Mark Stewart, Aliki Taylor, C. K. Wang, Shirley Wang, Yiduo Zhang, Ann Madsen   +42 more
wiley   +1 more source

HER2 Heterogeneity in Breast Cancer: Biological Basis, Clinical Implications, and Therapeutic Strategies. [PDF]

Breast Cancer (Dove Med Press)
Shi H, Feng Y, Guo T, Shou W, Li Y.
europepmc   +1 more source

HER2-positive tumors imaged within 1 hour using a site-specifically 11C-labeled Sel-tagged affibody molecule.

, 2012
A rapid, reliable method for distinguishing tumors or metastases that overexpress human epidermal growth factor receptor 2 (HER2) from those that do not is highly desired for individualizing therapy and predicting prognoses.
Jonas Grafström (145905), Erik Samén (18653320), Finn Dunås (12222861), Qing Cheng (18684607), Hanna-Stina Martinsson Ahlzén (19848630), Stefan Ståhl (154271), Sharon Stone-Elander (145935), Li Lu (68660), Elias Arnér (18684970), Helena Wållberg (3765691), Katarina Johansson (145928), Jan-Olov Thorell (145917), Maria Hägg Olofsson (15067675)   +12 more
core  

Characterization of Lysosomal Hydrolases and Transporters and Their Age‐Dependent Variability: Relevance to Drug Metabolism and Transport of Small Molecule and Biologic Drugs

Clinical Pharmacology &Therapeutics, EarlyView.
Lysosomes play a key role in the accumulation, catabolism, and transport of endogenous and exogenous metabolites and proteins and are involved in drug metabolism and prodrug activation. However, the protein abundance and interindividual variability of lysosomal drug‐metabolizing enzymes and transporters (DMETs) remain underexplored.
Darshak Gadara, Dilip Kumar Singh, Sandhya Subash, Guihua Yue, Deepak Ahire, Chris Bohl, Maciej Czerwinski, Stephanie Helmstetter, Scott Heyward, Robert S. Jones, Cyrus Khojasteh, Ryota Kikuchi, Priyanka Kulkarni, Bin Ma, Bernard Murray, Chris Seib, Bill Smith, David M. Stresser, Mitchell E. Taub, Ting Wang, Bhagwat Prasad   +20 more
wiley   +1 more source

ERBB2/HER2 landscape and prognostic impact: large-scale, real-world analysis across solid cancers. [PDF]

ESMO Open
Shreenivas A, Elliott A, Corbiere T, Chen HZ, George B, Kamgar M, Chakrabarti S, Desai A, Bracken-Clarke D, Xue E, Floudas CS, Thomas J, Xiu J, Sledge G, Antonarakis ES, Boumber Y, Kurzrock R.   +16 more
europepmc   +1 more source

Payload‐Based Clinical Pharmacology Review of Approved Antibody–Drug Conjugates: Commonalities and Considerations for Streamlined Development

Clinical Pharmacology &Therapeutics, EarlyView.
Antibody–drug conjugates (ADCs) combine the specificity of an antibody with the potency of a cytotoxic drug. Thirteen ADCs, utilizing seven unique cytotoxic payloads and targeting 11 distinct antigens, are currently approved by the US Food and Drug Administration as of June 2025, representing a rapidly growing and highly promising class of anticancer ...
Sijie Lu, Qingqing Xiao, Lixuan Qian, Siyuan Sun, Zhu Zhou, Michael Z. Liao, Chunze Li   +6 more
wiley   +1 more source